STOCK TITAN

Spectral AI, Inc. Warrants - MDAIW STOCK NEWS

Welcome to our dedicated page for Spectral AI Warrants news (Ticker: MDAIW), a resource for investors and traders seeking the latest updates and insights on Spectral AI Warrants stock.

Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.

Latest News: DALLAS, April 30, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that the company received the Commitment to Quality Achievement Award from the Texas Manufacturer Assistance Center (TMAC) for their UKCA Mark Attainment. “Spectral AI is honored to be recognized as an upcoming leader in the Texas Manufacturing space,” said Louis Percoco, Spectral AI’s General Manager. “Our mission is to bring innovation and solutions to wound care through the company’s DeepView™ technology with the utmost quality and a strong manufacturing backbone is vital as we continue driving towards commercialization of the product. We are proud to be part of the local business infrastructure and appreciate the support and recognition for the focus the team brought to the table by the Texas manufacturing community.” TMAC, which is associated with the Manufacturing Extension Partnership (MEP) of the National Institute of Standards and Technology (NIST) aims for Texas manufacturers to achieve profitable growth and increased competitiveness. The non-profit program supports Texas manufacturers by granting business management consulting services, new technologies implementation, operations streamlining, workforce development, and strategic planning. Their services extend beyond manufacturers and also include distribution, logistics, construction, healthcare, and government entities. This award heralds in a new era of quality excellence and leadership for Spectral AI as they move toward product commercialization.

Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) announced a $1 million investment from its largest shareholder into its subsidiary Spectral IP, focusing on advancing intellectual property in the AI ecosystem. The investment aims to unlock additional value for shareholders and accelerate innovation in medical diagnostics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.66%
Tags
AI
-
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) will report financial results for Q4 and full year 2023 on March 27, 2024. The company focuses on AI medical diagnostics for wound care. Investors can join the conference call to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.05%
Tags
-
Rhea-AI Summary
Spectral AI, Inc. (MDAI) secures a new $500,000 contract with the Defense Health Agency and the US Army Medical Material Development Activity for the development of the handheld version of DeepView™ Wound Imaging System. The Company has received over $149 million in non-dilutive financing in the past six months, bringing the total government support to over $250 million. The contract aims to optimize the device's functionality and size for combat readiness and potential use in home health care, reinforcing Spectral AI's position as a leader in AI-driven healthcare innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.56%
Tags
AI
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) forms a subsidiary to focus on advancing intellectual property in the AI healthcare sector, aiming to enhance shareholder value through patents and trade secrets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.18%
Tags
AI
-
Rhea-AI Summary
Spectral AI, Inc. appoints Peter M. Carlson as CEO, transitioning Wensheng Fan to Chief Innovation Strategist. The Company announces preliminary 2023 R&D revenue of $18 million and reaffirms $28 million revenue guidance for 2024. Spectral AI highlights first quarter momentum and key milestones in commercialization of AI-powered wound care technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
management AI
-
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) announces participation in investor conferences to showcase their AI technology for medical diagnostics in wound care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.1%
Tags
conferences AI
Rhea-AI Summary
Spectral AI, Inc. (MDAI) announces the UKCA authorization for its DeepView AI®-Burn predictive software, allowing for faster burn wound diagnosis. Revenue from UK commercialization in 2024 is expected to contribute to the Company's $28 million revenue guidance. The technology boasts 92% accuracy in distinguishing healthy and damaged tissue, potentially revolutionizing burn wound management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
none
-
Rhea-AI Summary
Spectral AI, Inc. appoints Dr. J. Michael DiMaio to its Board of Directors, extending lock-up agreements for major stockholders. Dr. DiMaio brings extensive medical and research expertise to support the company's AI-driven wound imaging technology platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
management AI
-
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) will participate in the BTIG Snowbird MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 13-14, 2024. The company will host investor meetings during the conference, offering an opportunity for virtual or in-person meetings. This event aims to showcase Spectral AI's focus on medical diagnostics for wound care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.67%
Tags
conferences AI
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) announced a Letter to Shareholders detailing the Company's progress towards commercializing its AI-driven DeepView System for wound assessment and treatment. The letter highlights a $149 million contract from BARDA, revenue generation expectations, FDA and UKCA marking for proprietary technology, promising interim results for DFU Clinical Study, and new management appointments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
AI

FAQ

What is the current stock price of Spectral AI Warrants (MDAIW)?

The current stock price of Spectral AI Warrants (MDAIW) is $0.12 as of September 5, 2024.

What is Spectral AI focused on?

Spectral AI Inc focuses on predictive medical diagnostics with its DeepView System.

What is the significance of the DeepView System?

The DeepView System distinguishes between damaged and healthy tissue for accurate healing assessments.

What recent achievement did Spectral AI have?

Spectral AI received the Commitment to Quality Achievement Award from TMAC for UKCA Mark Attainment.

Who is Louis Percoco?

Louis Percoco is Spectral AI's General Manager, leading the company towards innovation in wound care.

What does TMAC aim to achieve?

TMAC aims to help Texas manufacturers achieve growth and competitiveness through various support services.

Spectral AI, Inc. Warrants

Nasdaq:MDAIW

MDAIW Rankings

MDAIW Stock Data

17.61M
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
DALLAS